安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- YEZTUGO® (lenacapavir) for PrEP (pre-exposure prophylaxis)
What is YEZTUGO? YEZTUGO is a prescription medicine used as HIV-1 PrEP (pre-exposure prophylaxis) to reduce the risk of getting HIV-1 in adults and adolescents who weigh at least 77 pounds You must be HIV negative before and while receiving YEZTUGO
- U. S. FDA Accepts Gilead’s Application for Investigational Once Weekly . . .
Drug-resistant HIV-1 variants have been identified with use of YEZTUGO by individuals with undiagnosed HIV-1 infection Do not initiate YEZTUGO unless negative infection status is confirmed Individuals who acquire HIV-1 while receiving YEZTUGO must transition to a complete HIV-1 treatment regimen Contraindications
- Prescribing YEZTUGO (lenacapavir) | YEZTUGO HCP
YEZTUGO is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents (≥35 kg) who are at risk for HIV-1 acquisition Individuals must have a negative HIV-1 test prior to initiating YEZTUGO
- Yeztugo: Uses, Dosage, Side Effects, Warnings - Drugs. com
Yeztugo is used for HIV-1 PrEP to reduce the risk of getting HIV-1 in adults and adolescents who weigh at least 77 pounds (at least 35 kg) The initial dose consists of 2 Yeztugo injections (day 1) and 2 Yeztugo tablets (day 1 and day 2)
- Helpful Resources and Information | YEZTUGO HCP
YEZTUGO is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents (≥35 kg) who are at risk for HIV-1 acquisition Individuals must have a negative HIV-1 test prior to initiating YEZTUGO
- Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV . . .
Drug-resistant HIV-1 variants have been identified with use of Yeztugo by individuals with undiagnosed HIV-1 infection Do not initiate Yeztugo unless negative infection status is confirmed Individuals who acquire HIV-1 while receiving Yeztugo must transition to a complete HIV-1 treatment regimen Contraindications
- U. S. FDA Accepts Gilead’s Application for Investigational Once-Weekly . . .
Individuals must be tested for HIV-1 infection prior to initiating YEZTUGO, and with each subsequent injection of YEZTUGO, using a test approved or cleared by the FDA for the diagnosis of acute or
- For HCPs | Yeztugo® (lenacapavir) Dosing and Administration
This document is in response to your request for information regarding Yeztugo® (lenacapavir [LEN]) and oral and subcutaneous dosing and administration Some data may be outside of the US FDA-approved prescribing information
|
|
|